

FORM PTO-1390  
(REV 10/95)

U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

HUBR- 1186 ( 10102735)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/806635

INTERNATIONAL APPLICATION NO.

PCT/EP00/00623 ✓

INTERNATIONAL FILING DATE

27 January 2000 ✓

PRIORITY DATE CLAIMED

28 January 1999 ✓

TITLE OF INVENTION

USE OF A MELANOMA INHIBITING ACTIVITY FACTOR (MIA) FOR CARTILAGE AND BONE REPAIR ✓

APPLICANT(S) FOR DO/EO/US

Carola DONY, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is the **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
  2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
  3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).
  4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
  5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
    - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau.)
    - b. ☒ has been transmitted by the International Bureau.
    - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
  6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
  7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
    - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
    - b. ☐ have been transmitted by the International Bureau.
    - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
    - d. ☒ have not been made and will not be made.
  8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
  9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
  10. ☒ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Items 11. to 16. below concern document(s) or information included:
11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
  12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
  13. ☒ A **FIRST** preliminary amendment.
    - ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
  14. ☐ A substitute specification.
  15. ☐ A change of power of attorney and/or address letter.
  16. ☐ Other items or information:
  17. ☐ The follow fees are submitted
  18. ☐ Other

**BASIC NATIONAL FEE (37 CFR 1.492(A)(1) - (5)):**

Search Report has been prepared by the EPO or JPO ..... \$860.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
..... \$690.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482)  
but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ... \$710.00

Neither International preliminary examination fee (37 CFR 1.482) nor  
international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$1000.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
and all claims satisfied provisions of PCT Article 33(2)-(4) ..... \$100.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	17 - 20 =		x \$22.00
Independent	2 =	0	x \$78.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$250.00

\$

\$ 0

\$

**TOTAL OF ABOVE CALCULATIONS =**

\$990.00

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement  
must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

\$485.00

**SUBTOTAL =**

\$485.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

**TOTAL NATIONAL FEE =**

\$485.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property+

\$

**TOTAL FEES ENCLOSED =**

\$ 485.00

Amount to be:  
refunded

\$

charged


\$

- a. ☒ A check in the amount of \$485.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. 50-0624 in the amount of \$\_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit  
Account No. 50-0624. A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a)  
or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

James R. Crawford  
FULBRIGHT & JAWORSKI L.L.P.  
666 Fifth Avenue  
New York, NY 10103  
Customer No. 24972

  
SIGNATURE  
James R. Crawford  
NAME

April 2, 2001

39,155  
REGISTRATION NUMBER

EXPRESS MAIL NO.EL 829764253 US mailed April 2, 2001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Dony, et al.  
Serial No. : To Be Assigned  
Filing Date : Herewith  
For : USE OF A MELANOMA INHIBITING ACTIVITY  
FACTOR (MIA) FOR CARTILAGE AND BONE  
REPAIR

April 2, 2001

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

**PRELIMINARY AMENDMENT**

SIR:

In advance of prosecution, please amend the above-identified patent application as follows:

**IN THE CLAIMS:**

Cancel claims 1-17, without prejudice.

Add the following new claims:

18. A pharmaceutical composition comprising a melanoma inhibiting activity factor and at least one biocompatible and/or biodegradable matrix selected from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxylapatite, polylactic-coglycolid, polyanhydrides and collagen.
19. A pharmaceutical composition comprising a melanoma inhibiting activity factor (MIA) in combination with an osteoinductive protein.
20. A pharmaceutical composition as claimed in claim 19, wherein the ratio of osteoinductive protein : MIA is 1 : 1 to 1 : 20.
21. A pharmaceutical composition as claimed in claim 19, wherein said osteoinductive protein is selected from the group consisting of BMP-2, BMP-7 and a hedgehog protein.

22. A pharmaceutical composition as claimed in claim 19, wherein the composition comprises a biocompatible matrix.
23. A pharmaceutical composition as claimed in claim 18, wherein the biocompatible matrix is at least one member selected from the group consisting of hyaluronic acid, alginate, collagen, heparin, polylactic-coglycolid and/or polyactic-coglycolid derivatives or combinations thereof.
24. A method of inducing of the chondro-/osteogenic lineage and promoting cartilage and/or bone formation comprising administering an effective amount of the pharmaceutical composition of claim 18 to a subject..
25. The method of claim 24, wherein the composition further comprises an osteoinductive protein.
26. The method as claimed in claim 25, wherein said osteoinductive protein is selected from the group consisting of BMP-2, BMP-7 and a hedgehog protein.
27. The method as claimed in claim 25, wherein the ratio of osteoinductive protein : MIA is 1 : 1 to 1:20.
28. The method as claimed in claim 25 wherein the melanoma inhibiting activity factor (MIA) is combined with a biocompatible matrix.
29. The method as claimed in claim 28, wherein said biocompatible matrix comprises at least one member selected from the group consisting of hyaluronic acid, alginate, collagen, heparin, polylactic-coglycolid and polylactic-coglycolid derivatives.
30. A method for manufacturing a pharmaceutical composition to improve induction of the chondro/osteogenic lineage and to promote cartilage and/or bone formation an expression vector for a melanoma inhibiting activity factor (MIA) or a combination of a vector for the expression of an osteoinductive protein with a vector capable of expression of a melanoma inhibiting activity factor (MIA) .
31. A method for inducing the chondro-/osteogenic lineage and promoting cartilage and/or bone formation comprising administering the pharmaceutical composition prepared by the method of claim 30 to a subject.
32. The method claimed in claim 30, wherein the pharmaceutical composition comprises at least one biocompatible matrix selected from the group consisting of hyaluronic acid, alginate,

calcium sulfate, tricalcium phosphate, hydroxylapatite, polylactic-coglycolid, polyanhydrides and collagen.

33. The method comprising bone and/or cartilage in a patient comprising administering an effective amount of a melanoma inhibiting activity factor (MIA) to the patient.

34. The method according to claim 33, further comprising co-administering an osteoinductive protein is used.


**REMARKS**

The purpose of this amendment is to conform the claims to U.S. practice.

Respectfully submitted,

**FULBRIGHT & JAWORSKI L.L.P.**

By

  
James R. Crawford  
Reg No. 39,155

666 Fifth Avenue  
New York, N.Y. 10103  
(212) 318-3000

09805635 060401  
T04090" 5E990860

Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair

The present invention relates to a method and a composition for the induction of the chondro-/osteogenic lineage from mesenchymal stem cells and for promoting cartilage and bone formation using a melanoma inhibiting activity factor (MIA) preferably in combination with an osteoinductive protein.

MIA was initially described as a factor inhibiting the growth of malignant melanoma cell line HTZ-19 (Weilbach et al., Cancer Res. 50 (1990) 6981-6986). Cloning and purification of the factor resulted in a novel 11 kD protein with anti-tumor activity (WO 95/03328). The bovine homolog CD-RAP (cartilage derived-retinoic acid-sensitive protein) was detected in cartilage primordia and cartilage (Dietz, U., and Sandell, L., J. Biol. Chem. 271 (1996) 3311-3316). The mouse CD-RAP/MIA gene was localized in embryonic mouse cartilage and the transcripts were detected in chondrosarcomas (Bosserhoff et al., Developmental Dynamics 208 (1997) 516-525). These data point to a normal expression of MIA in cartilage. Further data are derived from transgenic mice where MIA promoter directs the cartilage specific expression of lacZ (Xie et al., 44<sup>th</sup> Annual Meeting, Orthopaedic Research Society, March 16-19, 1998, New Orleans, Louisiana). MIA could also be used as a progression marker for malignant melanoma (Bosserhoff et al., Cancer Research 57 (1997) 3149-3153; DE 196 53 358 A1)

Osteoinductive proteins are proteins which induce the full developmental cascade of endochondral bone formation towards chondrocytes and osteocytes and are, for example, hedgehog proteins (Sonic (Shh), Indian (Ihh), Desert (Dhh); Kinto et al., Kinto et al., FEBS Letters 404 (1997) 319-323), or members of the bone morphogenetic protein family (BMPs).

Hedgehog proteins, especially sonic hedgehog (Shh) are responsible for the development of multiple organ systems, including brain, spinal cord, craniofacial structures, limbs, the eye, left and right body symmetry, somite patterning (Hammerschmidt et al., Trends Genet. 13 (1997) 14-21). Indian hedgehog (Ihh) plays a role in cartilage development (Vortkamp et al., Science 273 (1996) 613-622; Lanske et al., Science 273 (1996) 663-666). Desert hedgehog (Dhh) is involved in the development of male germ line cells. Further evidence for involvement of hedgehog, e.g. Shh, in bone development and repair is given by mutations leading

to human holoprosenphaly (Roessler et al., Human Molecular Genetics 6 (1997) 1847-1853; Belloni et al., Nature Genetics 14 (1996) 353) and by the induction of ectopic bone after expressing Shh in fibroblasts and transplantation of the cells in muscles (Nakamura et al., BBRC 237 (1997) 465-469); Kinto et al., FEBS Letters 404 (1997) 319-323).

Bone morphogenetic proteins (BMPs) are molecules which are responsible for the formation of bone, cartilage, tendon, and other tissues, shown by ectopic bone formation (Wozney et al., Science 272 (1988) 738-741). The unique inductive activities of these proteins, along with their presence in bone, suggest that they are important regulators of bone repair processes and may be involved in the normal maintenance of bone tissue. Many such proteins are known which can be divided into several sub-families (Reddi, A.H., Cytokine & Growth Factor Reviews 8 (1997) 11-20). Such BMPs are, for example, BMP-2 to BMP-14 and the growth and developmental factors GDF-1 to GDF-14.

BMPs are important signaling factors and regulate the multistep sequential cascade in bone and cartilage formation such as chemotaxis, mitosis and differentiation. Especially, BMP-2, BMP-3, BMP-4, BMP-5, BMP-7 initiate chondrogenesis and osteogenesis.

In the case of promoting bone healing, only limited success has been achieved. Currently, large bone defects (orthopedic reconstruction) are treated with either bone or bone powder grafting either autografts or allografts. In addition, in all cases of bone fractures about 5-10% show difficulty in healing, either delayed union (healing only after 6 month) or no healing (non-union still after 9 month) (Einhorn, T.A., Journal of Bone and Joint Surgery, American Volume 77A (1995) 940-956). Allograft bone and bone powder are derived from human donors and can be stored in bone tissue banks, but are limited. Since it is human material, extensive screening for viral (e.g. HIV, HBV, HCV) and bacterial contamination is necessary. Also graft rejections may occur. The material varies in quality depending on donor. The use of autologous bone is often accompanied by morbidity at the graft site (Muschler et al., Clin. Orthop. Rel. Res. (1996) 250-260). In addition there is only a limited amount of such a material available from the autologous donor.

Clinical trials for BMP-2 and BMP-7 alone to promote bone healing have been started. The first results indicate that BMP-2 or BMP-7 seem to be equivalent to bone or bone powder grafts (Boyne, J. Oral Maxillofac. Surg. 53 Suppl 4 (1995) 92; Kirker-Head et al., Clin. Orthop. 218 (1995) 222; Johnson et al., Clin. Orthop. 277 (1992) 229). About 2.5 to 6.8 mg per g matrix are used.

There is a high medical need for improved and enhanced cartilage repair. Current therapies for acute defects (e.g. car or sport accidents), either partial thickness, full thickness or gap defects, are excision, debridement or waiting for very rarely occurring self-healing. There are some therapies under investigation, e.g. mosaic plastic, using autogenous bone/cartilage graft in the shape of a cylinder for large defects. There are a few cell therapy approaches in preclinical and premarketing studies. Autologous chondrocytes isolated during a biopsy are cultivated in vitro as a monolayer (Brittberg et al., N. Engl. J. Med. 331 (1994) 889-895). The dedifferentiated cells are injected under a periosteal flap sutured over the defect in an open knee surgery. Mesenchymal stem cells are in preclinical studies which can differentiate into chondrocytes on an appropriate carrier (US-P 5,486,359). There exists no easy-to-use therapy yet using a protein or combinations of proteins.

WO 98/30234 describes a composition of BMP and hedgehog proteins. WO 97/21447 describes a combination of osteoinductive bone morphogenetic protein (e.g., BMP-7) and a morphogenetic protein stimulating factor IGF-1 for bone healing. WO 92/09697 describes a combination of BMP and TGF- $\beta$  for such purposes. Factors healing cartilage either alone or in combination are described in WO 96/14335 (cartilage derived morphogenetic proteins) and WO 97/23612.

Further combinations of factors for bone healing are described in US-P 5,270,300: osteogenic factor (TGF-beta, TGF-beta and EGF, osteogenin, BMP, + combinations thereof) and angiogenic factor (TGF-beta, angiogenin, angiotropin, FGF-2, PDGF-a and combinations thereof) for bone healing; in US-P 5,629,009: TGF-beta, EGF, or factors derived from demineralized bone matrix (between about 10 and 90 % by weight of matrix) combined with FGF or PDGF; in EP-B 0 429 570 by Genetics Institute, Inc.: combination of BMPs (protein or DNA) with different type of carriers. There are also mentioned combinations of BMPs with EGF, FGFs, PDGF, TGF-alpha and TGF-beta.



The invention provides a method for improved induction of the chondro-/osteogenic lineage and promoting cartilage and enhanced bone formation, using MIA, preferably in combination with an osteoinductive protein.

5 The invention further relates to a method for manufacturing a pharmaceutical composition for induction of the chondro-/osteogenic lineage and the promotion of cartilage and bone formation, wherein a melanoma inhibiting activity factor (MIA) according to the invention is used as an essential component of this pharmaceutical composition. It is further preferred to use a combination of MIA and an osteoinductive protein as essential components. The ratio of osteoinductive  
10 protein : MIA is preferably 1 : 1 to 1 : 20.

It was surprisingly found that MIA, preferably in combination with an osteoinductive (osteogenic) protein, preferably with a bone morphogenetic protein 2, 3, 4, 5 or 7 or a hedgehog protein, results in cartilage and/or bone formation.

By "osteoinductive protein" is preferably understood an osteogenic protein which  
15 induces endochondral bone formation. Chondrocytes produce cartilageneous matrix followed by osteoblasts and osteocytes which produce bone tissue. Early genes of the chondro-/osteogenic lineages, e.g. Cbfa1, are thereby upregulated, and this ultimately leads to the formation of chondrocytes and osteocytes. Such an osteoinduction can be achieved, for instance, through BMPs or hedgehog proteins.  
20 BMP-2, BMP-7, or hedgehog protein (Shh, Ihh or Dhh) is preferred. The osteoinductive proteins useful in this invention include also proteins such as TGF- $\beta$ , BMPs, and TGF- $\beta$  combined with EGF.

A substance's ability to induce osteogenesis can be tested in a simple manner. For this purpose, for example, pluripotent mesenchymal cells, e.g., C3H10T1/2 cells, are  
25 cultured with and without the potential osteoinductive factor. Controls and treated cells are measured for alkaline phosphatase activity. The activity can be measured photometrically using a suitable colorimetric substrate, e.g., p-nitrophenyl phosphate (Nakamura et al., BBRC 237 (1997) 465-469). Increased activity of alkaline phosphatase is scored as osteoinduction. Alternatively, upregulation of  
30 osteocalcin and alkaline phosphatase is measured by RT-PCR using suitable primers for osteocalcin and alkaline phosphatase.

A compound's ability to induce chondrogenesis can be tested in vitro using pluripotent mesenchymal cells, e.g. C3H10T1/2 or pre-chondrogenic cells, e.g. RCJ3.1C5.18. The cells are cultivated in three-dimensional cultures, e.g. micromass culture with the inductor or a combination of inductors for two to three weeks.

5 Collagen type II as cartilage marker could be proven either by immunocytochemistry using monoclonal antibodies or by Northern blot after RNA isolation. Alcian blue staining proves the existence of proteoglycans. A different method would be to test for aggrecan using specific primers in RT-PCR reaction.

10 In a further preferred embodiment of the invention, MIA, preferably in combination with an osteogenic protein, can be introduced in the cells via gene therapy methods ex vivo or in vivo. For this method the genes coding for MIA, and optionally, for the osteogenic protein are introduced in one vector, preferably under the control of the same promoter, or in separate vectors. For an efficient expression of MIA and the osteogenic protein, it is necessary to use strong promoters in the vectors. Such promoters are, e.g., PGK or CMV promoters.

15 Preferably, the expression vector consists of such a strong promoter, the full-length mRNA of the chosen gene, e.g., BMP-2, BMP-3, BMP-4, BMP-5, BMP-7, Shh, Ihh, or Dhh, FGF, HGF, PlGF, VEGF, an artificial intron and a poly-A-site. For in vivo application, DNA is either lyophilized to collagen sponges, preferably for

20 osteogenesis, or applied with any other suitable carrier, preferably hyaluronic acid or collagen for application as a gel for chondrogenesis. For ex vivo application, cells of the chondrogenic and osteogenic lineage are transfected with such vectors and subsequently implanted.

25 The pharmaceutical formulation according to the invention may also include an appropriate matrix, for instance, for delivery and/or support of the composition and/or providing a surface for bone formation. The matrix may provide slow release of MIA, preferably in combination with an osteoinductive protein. Slow release for MIA is possible by combining MIA with a matrix to which MIA is bound in a reversible manner by ionic or hydrophobic interaction. Preferably, the

30 composition includes a matrix which is biocompatible and/or biodegradable. Potential matrices for the compositions contain, for example, hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxylapatite, polylactic-coglycolid, polyanhydrides, collagen, or combinations of these, whereby hyaluronic

acid, alginate, heparin, collagen and/or polylactic-coglycolid or derivatives thereof are preferred.

For local bone repair, it is preferred to use MIA or its combination with the osteoinductive protein. It is therefore preferred to use for osteogenesis form-stable matrices in close contact with the progenitor cells. MIA or the combination applied to a three-dimensional matrix like a sponge and put tightly into the defect enable cells, e.g. from periost or bone marrow, to proliferate and differentiate into bone cells which are preferably biodegradable. Preferred materials for such sponges are, for example, collagen, alginate, tricalcium phosphate, hydroxylapatite and combinations thereof.

For the induction of chondrogenesis, it is essential that MIA or its combination with the chondrogenic/osteogenic protein should be directed to the local cartilage defect. Cartilage progenitor cells are derived either from the subchondral bone (in full thickness defects) or from the synovial membrane (in partial thickness defects). The treatment enables the cells to proliferate and to differentiate which results in the synthesis of new cartilage. Mature chondrocytes from the surrounding area could be stimulated, too. To this end, it is expedient that the pharmaceutical composition should be applied directly onto, or into, the cartilage tissue, preferably by local implantation or local injection. Suitably, this is done by means of a syringe. Here, again, the use of a matrix is preferred. However, it is preferred that this matrix, rather than being form-stable, should be flowable like a gel or a paste. Preferably, the flowability is high enough to allow the pharmaceutical formulation to be applied with a syringe.

The dosage regimen will be determined by the attending physician, considering various facts which modify the action of the formulation of the invention. Factors which may modify the action of the formulation include the amount of bone desired to be formed, the site of application, the condition of the damage, the patient's age, sex and diet, the severity of any infection, time of administration, and other clinical factors. The dosage may vary with the type of the matrix used in the reconstitution of bone.

The invention further relates to a process for the production of a pharmaceutical agent which is characterized in that MIA is used as an essential component of this

agent. In this process, it is preferred to use 500 µg of MIA per implant or per bolus injection. In a preferred embodiment, the pharmaceutical agent contains in addition an osteoinductive protein. The weight ratio of osteoinductive protein : MIA is preferably 1 : 1 to 1 : 20. It is thus preferred to use an excess amount of MIA. In this composition, it is preferred to use about 100 µg of osteoinductive protein and about 500 µg of MIA. The overall amount of MIA and osteoinductive protein is preferably in the range between 200 and 800 µg, referred to gram of matrix protein.

For the cartilage applications, such a pharmaceutical formulation is preferably a gel based on a hyaluronic or collagen matrix. Such a gel is preferably injectable and is applied in an amount of 100 µl to 2 ml per bolus injection. In the case of application in the bone, the use of a collagen sponge is preferred.

The invention further relates to a pharmaceutical composition of this kind. A pharmaceutical composition of this kind can be applied for bone repair, osteogenesis in vivo, especially for the treatment of patients who suffer from bone defects and hence are in need of bone repair as well as for cartilage repair.

A further object of the invention is a pharmaceutical composition containing an expression vector for MIA, and optionally, in addition, for an osteoinductive protein, or a combination of a vector for the expression of MIA with a vector capable of expression of an osteoinductive protein, as well as a method for manufacturing such a pharmaceutical composition.

The following examples and references are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

#### Example 1

##### In vitro cell assay for induction of osteogenic differentiation

Mesenchymal cells, e.g. C3H10T1/2 cells are seeded into 96 well plates. After 24 hours, the osteoinductive factor, e.g. hedgehog or BMP, is added alone or in combination with MIA (see Table 1). For control, cells are untreated. After 5 days

control and treated cells are analyzed for alkaline phosphatase activity and protein content. Alkaline phosphatase (AP) activity is measured photometrically using p-nitrophenyl phosphate as a colorimetric substrate. Increase in activity is scored as osteoinduction. For hedgehog 0.05 µg/ml was applied. MIA was tested in various concentrations from 0.05 µg/ml to 50 µg/ml.

MIA applied alone did not change the alkaline phosphatase activity. When MIA was applied in combination with hedgehog a synergistic effect was observed resulting in 2.7 fold increase of alkaline phosphatase activity.

Table 1

Factor	µg/ml	mmol PNP/min/mg protein	% of control
Hedgehog	0.05	14.43	309
MIA	50	4.26	91
MIA	10	3.85	83
MIA	5	4.14	89
MIA	1	3.98	85
MIA	0.5	3.71	79
MIA	0.1	3.77	81
MIA	0.05	4.86	104
Hedgehog + MIA	0.05 + 50	39.23	839
Hedgehog + MIA	0.05 + 10	26.60	569
Hedgehog + MIA	0.05 + 5	30.57	654
Hedgehog + MIA	0.05 + 1	16.11	345
Hedgehog + MIA	0.05 + 0.5	20.08	429
Hedgehog + MIA	0.05 + 0.1	25.09	536
Hedgehog + MIA	0.05 + 0.05	21.09	451
negative control		4.67	100

Example 2

## In vitro assay for induction of cartilage markers

5 Chondrocytes of pigs were isolated from femoral condyles. Primary human chondrocytes were isolated from femoral condyles of patients undergoing knee surgery. The cartilage was minced into small pieces and incubated in 10 ml with 2 mg/ml of collagenase (Roche Diagnostics GmbH, DE) and 0.1 mg/ml of hyaluronidase (Sigma) and 0.15 mg/ml DNase (Roche Diagnostics GmbH, DE) for 16 h at 37°C. After centrifugation, the chondrocytes were seeded in petri dishes for proliferation.

10 The dedifferentiated cells were used for assays.  $2 \times 10^4$  cells in 10  $\mu$ l medium were spotted per well in 96-well plates. After 4 h, 200  $\mu$ l medium were added. After 7 days, inductors were added to the micromass culture: BMP-2, hedgehog, MIA, and combinations thereof. Two to four weeks later, the cultures were assayed for cartilage markers. Morphologically, chondrocytes are visible by their round appearance. Immunocytochemistry shows collagen type II expression. 15 Cytochemically, Alcian blue proves sulfated proteoglycans. With PCR, aggrecan and SOX9 could be shown.

Example 3

## In vitro assay for induction of proliferation

20 Chondrocytes were isolated from the femoral condyles of pigs. 3,000 cells were seeded in 96 well plates and cultivated for 3 days. After 24 h of serum-free incubation, MIA, BMP-2, Shh and combinations thereof were added. During the last 16 h of the 48 h serum-free induction period, BrdU labeling was present. The detection ELISA was done according to the instructions of the manufacturer 25 (Roche Diagnostics GmbH).

Table 2

factor	ng/ml concentration	% stimulation above serum-free control
hedgehog	100	88
	50	93
BMP-2	500	112
	100	69
MIA	50,000	195
	10,000	85
	2,000	99
MIA + BMP-2	50,000 + 500	125
	10,000 + 500	237
	50,000 + 100	203
	10,000 + 100	133
MIA + hedgehog	50,000 + 100	115
	10,000 + 100	224
	50,000 + 50	261
	10,000 + 50	131
fetal calf serum		792
serum-free control		100

MIA alone and in combination stimulates DNA synthesis of primary chondrocytes.

#### Example 4

##### 5 In vitro organ assay to study chondrogenesis: mouse limb bud assay

10 Limb buds are isolated from E12.5 to E15.5 mouse embryos (NMRI) using microdissection scissors and watchmaker's forceps under sterile conditions. The limb buds were rinsed in PBS containing an antibiotic-antimycotic from Gibco-BRL (#15240-039), then cultured in serum-free BGJb medium from Gibco-BRL (#12591-020) for 48 h to 144 h in organ culture dishes. After 24 h of culture MIA, BMP-2 alone or various combinations of MIA and BMP were added. Media were changed every day. At the end of the culture the limbs were rinsed in PBS, then fixed overnight in 4% paraformaldehyde, either processed for paraffin embedding

or for wholemount in situ hybridization as described by Wilkinson, D.G., In situ hybridization: a practical approach, In: Rickwood D, Hames BD (eds.) The practical approach series, Oxford Univ. Press, Oxford, New York, Tokyo (1992). Paraffin sections were stained with von Kossa to visualize and quantitate the amount of calcified areas, stained with Alcian blue to assess chondrogenesis. In addition in situ RNA hybridization was performed to analyze gene expression characteristic for cartilage development, e.g. collagen II, MIA, collagen X.

#### Example 5

##### Mouse bioassay for cartilage, bone, tendon and ligament induction

Similar to the Sampath and Reddi rat ectopic implant assay, a mouse ectopic implant assay, using inbred C3H mice, 4 months old was performed (Sampath and Reddi, Proc. Natl. Acad. Sci. USA 80 (1983) 6591-695; WO 95/16035). (a) MIA alone, (b) BMP-2 alone and (c) combinations of MIA and BMP-2 were applied in the appropriate buffer, 0.1% trifluoroacetic acid for BMP-2 and 100 mM potassium-phosphate, 150 mM NaCl, pH 6.0 for MIA. As carrier were used collagen type I matrix and hyaluronic acid. Any suitable carrier maybe used, e.g. collagen type I matrix, collagen-heparin mixture, gelatin capsules, hyaluronic acid, alginate or other functionally equivalent device, based on biocompatibility, biodegradability, stability and mechanical properties.

The implants were placed intramuscular into the gluteus muscle of the mouse and left for 14 days. After 14 days the mice were sacrificed by cervical dislocation. The implants were isolated and processed using standard histological techniques (see Theory and Practice of Histological Techniques, ed. Bancroft and Stevens, Churchill Livingstone, 1996). Paraffin sections (4  $\mu$ m) were cut and stained with von Kossa to visualize and quantitate the amount of cartilage and bone tissue induced in each implant. Positive (e.g. BMP-2) and negative (e.g. mock device) implant control groups were compared to experimental implants.

To assess the quality of cartilage and/or bone induced, gene expression can be studied by RNA in situ hybridization for cartilage and bone markers as described above, using cartilage markers (e.g. collagen II, collagen X) and bone markers (e.g. collagen I, osteocalcin).



Example 6

Mouse bioassay for cartilage, bone, tendon and ligament induction for DNA expression vectors

5 Similar to the Sampath and Reddi rat ectopic implant assay, a mouse ectopic implant assay, using e.g. outbred NMRI mice or inbred C3H mice, 2 months old was performed (Sampath and Reddi, Proc. Natl. Acad. Sci. USA 80 (1983) 6591-695; WO 95/16035. Expression vectors for (a) osteoinductive factor alone, (b) MIA alone and (c) combinations of osteoinductive factor and MIA were lyophilized in the appropriate buffer, e.g. TE-buffer (Fang et al., Proc. Natl. Acad. Sci. USA 93  
10 (1996) 5753-5758). Any suitable carrier may be used, e.g. collagen type I matrix, collagen-heparin mixture, gelatin capsules, hyaluronic acid, alginate or other functionally equivalent device, based on biocompatibility, biodegradability, stability and mechanical properties.

15 The implants were set intramuscular into the hindlimb muscle of the mouse for seven and 14 days. After seven and 14 days the mice were sacrificed by cervical dislocation. The implants were isolated and processed using standard histological techniques (see Theory and Practice of Histological Techniques, ed. Bancroft and Stevens, Churchill Livingstone, 1996). Paraffin (4  $\mu$ m) sections can be stained with Toluidine Blue, Alcian Blue, von Kossa, Movat or Hematoxylin/Eosin to visualize  
20 and quantitate the amount of tendon, ligament, cartilage and bone tissue induced in each implant. Positive (e.g. BMP-2, shh expression vector) and negative (e.g. mock device) implant control groups are compared to experimental implants.

To assess the quality of cartilage and/or bone induced, gene expression can be studied by RNA in situ hybridization for cartilage and bone markers as described  
25 above.

Example 7

Non-union fracture model in rabbits (radius osteotomy)

30 A non-union defect of 1.5 cm in length was produced at the radius of adult rabbits in order to assess the ability of the combinations of MIA alone and MIA in combination with BMP or hedgehog proteins and appropriate carrier to affect bone repair. The animals were anesthetized by intravenous injection of

5 xylazine/ketamine, and surgery was carried out under sterile conditions. The defect was either left empty, filled with the appropriate carrier, or filled with a carrier containing MIA and BMP, or each of these factors alone. Animals were allowed to move freely and X-rays were carried two and four weeks after surgery in order to assess the rate of bone defect healing. At the end of study, the animals were killed under anesthesia and the bone defect site was removed for histological examination using the von Kossa and Goldner stain so as to quantify and characterize the quality of newly formed repair tissue.

#### Example 8

##### 10 Full thickness articular cartilage repair model

15 A full thickness articular cartilage defect model in the femoral-patellar joint of adult rabbits is used to assess the ability of MIA alone or in combination with BMP or hedgehog protein and carrier to affect cartilage and bone repair. Adult rabbits are anesthetized and prepared for sterile surgery. An up to 4 x 4 mm defect through articular cartilage and into underlying subchondral bone is drilled into the patellar groove of the knee joint. The defect is either left empty, filled with the appropriate carrier, or filled with a carrier containing MIA alone or in combination with BMP or hedgehog protein. Animals are allowed to move freely for four weeks. After four weeks the animals are humanely euthanized and the articular cartilage/subchondral bone defect site is evaluated histologically for tissue architecture, quantity and quality of the repair.

#### Example 9

##### Partial thickness articular cartilage repair model

25 A partial thickness articular cartilage defect model in the femoral-patellar joint of adult rabbits is used to assess the ability of MIA alone or in combination with BMP or hedgehog protein and carrier to affect cartilage and bone repair. Adult rabbits are anesthetized and prepared for sterile surgery. An up to 4 x 4 mm hole is drilled through articular cartilage into the patellar groove of the knee joint, leaving the underlying subchondral bone intact. The defect is either left empty, filled with the appropriate carrier, or filled with a carrier MIA alone or in combination with BMP or hedgehog protein. Animals are allowed to move freely for four weeks. After four

weeks the animals are humanely euthanized and the articular cartilage defect site is evaluated histologically for tissue architecture, quantity and quality of the repair.

090635 060401  
T04090 SE990850

List of References

- Belloni et al., Nature Genetics 14 (1996) 353
- Bosserhoff et al., Cancer Research 57 (1997) 3149-3153
- 5 Bosserhoff et al., Developmental Dynamics 208 (1997) 516-525
- Boyne, J. Oral Maxillofac. Surg. 53 Suppl 4 (1995) 92
- Brittberg et al., N. Engl. J. Med. 331 (1994) 889-895
- DE 196 53 358 A1
- Dietz, U., and Sandell, L., J. Biol. Chem. 271 (1996) 3311-3316
- 10 Einhorn, T.A., Journal of Bone and Joint Surgery, American Volume 77A (1995)  
940-956
- Fang et al., Proc. Natl. Acad. Sci. USA 93 (1996) 5753-5758
- Hammerschmidt et al., Trends Genet. 13 (1997) 14-21
- Johnson et al., Clin. Orthop. 277 (1992) 229
- 15 Kinto et al., FEBS Letters 404 (1997) 319-323
- Kirker-Head et al., Clin. Orthop. 218 (1995) 222
- Lanske et al., Science 273 (1996) 663-666
- Muschler et al., Clin. Orthop. Rel. Res. (1996) 250-260
- Nakamura et al., BBRC 237 (1997) 465-469
- 20 Reddi, A.H., Cytokine & Growth Factor Reviews 8 (1997) 11-20
- Roessler et al., Human Molecular Genetics 6 (1997) 1847-1853
- Sampath and Reddi, Proc. Natl. Acad. Sci. USA 80 (1983) 6591-695
- Theory and Practice of Histological Techniques, ed. Bancroft and Stevens,  
Churchill Livingstone, 1996
- 25 US-P 5,270,300
- US-P 5,486,359
- US-P 5,629,009
- Vortkamp et al., Science 273 (1996) 613-622
- Weilbach et al., Cancer Res. 50 (1990) 6981-6986
- 30 Wilkinson, D.G., In situ hybridization: a practical approach, In: Rickwood D,  
Hames BD (eds.) The practical approach series, Oxford Univ. Press,  
Oxford, New York, Tokyo (1992)
- WO 95/03328
- WO 95/16035
- 35 WO 96/14335
- WO 97/21447

WO 97/23612

WO 98/30234

Wozney et al., Science 272 (1988) 738-741

Xie et al., 44<sup>th</sup> Annual Meeting, Orthopaedic Research Society, March 16-19, 1998,  
New Orleans, Louisiana

5

090635-050401

02 Jan. 2001

International Application  
No. PCT/EP00/00623  
Dr. Carola Dony

JC08 Rec'd PCT/PTO 02 APR 2001

ART 34 AMDT

## New Claims

1. A pharmaceutical composition containing a melanoma inhibiting activity factor and a biocompatible and/or biodegradable matrix selected from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxylapatite, polylactic-coglycolid, polyanhydrides, collagen, or combinations of these.
2. A pharmaceutical composition containing a melanoma inhibiting activity factor (MIA) in combination with an osteoinductive protein.
3. A pharmaceutical composition as claimed in claim 2, wherein the ratio of osteoinductive protein : MIA is 1 : 1 to 1 : 20.
4. A pharmaceutical composition as claimed in claim 2 or 3, wherein the osteoinductive protein is BMP-2, BMP-7 or a hedgehog protein.
5. A pharmaceutical composition as claimed in claims 2 to 4, wherein the composition includes a biocompatible matrix.
6. A pharmaceutical composition as claimed in claim 1 or 5, wherein the biocompatible matrix is hyaluronic acid, alginate, collagen, heparin, polylactic-coglycolid and/or polylactic-coglycolid derivatives or combinations thereof.
7. Use of a melanoma inhibiting activity factor (MIA) as the essential component for manufacturing a pharmaceutical composition for improved induction of the chondro-/osteogenic lineage and promotion of cartilage and/or bone formation.

8. A use according to claim 7, wherein the composition contains in addition an osteoinductive protein.
9. A use as claimed in claim 8, wherein the osteoinductive protein is BMP-2 or BMP-7 or a hedgehog protein.
10. A use as claimed in claim 8 or 9, wherein the ratio of osteoinductive protein : MIA is 1 : 1 to 1 : 20.
11. A use as claimed in claims 8 to 10, wherein the melanoma inhibiting activity factor (MIA) is combined with a biocompatible matrix.
12. A method as claimed in claim 11, wherein the biocompatible matrix is hyaluronic acid, alginate, collagen, heparin, polylactic-coglycolid and/or polylactic-coglycolid derivatives or combinations thereof.
13. Use of an expression vector for a melanoma inhibiting activity factor (MIA) or a combination of a vector for the expression of an osteoinductive protein with a vector capable of expression of a melanoma inhibiting activity factor (MIA) for manufacturing a pharmaceutical composition for improved induction of the chondro-/osteogenic lineage and promotion of cartilage and/or bone formation.
14. A use of an expression vector capable of expression of a melanoma inhibiting activity factor (MIA) or a vector capable of expression of an osteoinductive protein and a vector capable of expression of a melanoma inhibiting activity factor (MIA) as essential component for manufacturing a pharmaceutical composition for improved induction of the chondro-/osteogenic lineage and promotion of cartilage and/or bone formation.

**ART 34 AMDT**

3

15. A use as claimed in claim 13, wherein the composition includes a biocompatible matrix selected from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxylapatite, polylactic-coglycolid, polyanhydrides, collagen, or combinations of these.
16. The use of a melanoma inhibiting activity factor (MIA) for the treatment of a patient in need of bone and/or cartilage repair.
17. The use according to claim 18, wherein a combination of a melanoma inhibiting activity factor (MIA) and an osteoinductive protein is used.



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 38/57, C07K 14/47, A61L 27/22, 27/54</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/44401</b> <b>(43) International Publication Date:</b> 3 August 2000 (03.08.00)
<b>(21) International Application Number:</b> PCT/EP00/00623 <b>(22) International Filing Date:</b> 27 January 2000 (27.01.00)  <b>(30) Priority Data:</b> 99101315.2      28 January 1999 (28.01.99)      EP  <b>(71) Applicant (for all designated States except US):</b> F. HOFFMANN-LA ROCHE AG [CH/CH]; CH-4070 Basle (CH).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> DONY, Carola [DE/DE]; Engelstrasse 7, D-81477 München (DE). PROETZEL, Gabriele [DE/DE]; Adenauerplatz 1, D-97523 Schwanfeld (DE). LESER, Ulrike [DE/DE]; Elisabethstrasse 26, D-80796 München (DE).  <b>(74) Agent:</b> SCHREINER, Siegfried; Roche Diagnostics GmbH, Patent Department Pharma (TR-E), P.O. Box 11 52, D-82372 Penzberg (DE).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> USE OF A MELANOMA INHIBITING ACTIVITY FACTOR (MIA) FOR CARTILAGE AND BONE REPAIR  <b>(57) Abstract</b>  A melanoma inhibiting activity factor (MIA), preferably in combination with an osteoinductive protein, is a useful pharmaceutical agent for promoting bone healing and/or cartilage repair.		

28/05/2001 09:11 SCIL HOLDING → 045563999  
17/05/2001 16:55 650 752 0202  
03/17/01 08:55 FAX 050 752 0202 DELTAGEN  
17/05/2001 16:39 SCIL HOLDING → 00016507520202

002/006  
NR.285 002

002/006  
NR.257 002



### DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My resident, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair". the specification of which

( ) is attached hereto.  
(x) was filed on 27 January 2000 International as Application Serial No. PCT/EP00/00623

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

#### Foreign Priority Applications

I hereby claim foreign priority benefits under Title 35, United States Code 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

#### Priority Claimed

<u>99 101 315.2</u>	<u>Europe</u>	<u>28/January/1999</u>	Yes (x) No ( )
(Number)	(Country)	(Day/Month/Year Filed)	
			Yes ( ) No ( )
(Number)	(Country)	(Day/Month/Year Filed)	

003/006  
NR.285 023

28/05/2001 09:11 SCIL HOLDING → 045563999  
17/05/2001 16:55 650 752 0202  
08/17/01 08:35 FAX 650 752 0202 DELTAGEN  
17/05/2001 16:39 SCIL HOLDING → 00016507520202

003/006  
NR.257 023

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

U.S. Priority Applications

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)
----------------------	---------------	-------------------------------------

(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)
----------------------	---------------	-------------------------------------

Power of Attorney

I hereby appoint the following attorneys and patent agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Peter F. Felte, Reg. No. 20,297; John E. Lynch, Reg. No. 20,940; Norman D. Hanson, Reg. No. 30,946; John A. Bauer, Reg. No. 32,554; Mary Anne Schofield, Reg. No. 36,669; James Zubok, Reg. No. 38,671; James R. Crawford, Reg. No. 39,155; Andrew Im, Reg. No. 40,637 and David Rubin, Reg. No. 40,314; my attorneys with full power of substitution and revocation.

28/05/2001 09:11 SCIL HOLDING → 045563999

17/05/2001 16:55 650 752 0202

05/17/01 08:55 FAX 650 752 0202 DELTAGEN

17/05/2001 16:39 SCIL HOLDING → 00016507520202

004/006

NR.267 024

Address all telephone calls to \_\_\_\_\_ at (212) 318-3000.

Address all correspondence to: FULBRIGHT & JAWORSKI L.L.P.  
666 Fifth Avenue  
New York, New York 10103

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-10 (1) Carola Dony C. Dony 10/05/01  
Full Name/Sole or First Inventor Signature Date

Residence: 81477 München  
Germany OEX

Post Office Address: Engelstraße 7  
81477 München/Germany

Citizenship: German

2-10 (2) Gabriela Proetz G. Proetz 17/05/01  
Full Name/Second Inventor Signature Date

Residence: 97523 Schwanfeld OEX  
Germany

Post Office Address: Adenauerplatz 1  
97523 Schwanfeld/Germany

Citizenship: German

28/05/2001 09:11 SCIL HOLDING → 045563999  
28/05/2001 09:28 +49 8856 605414  
28/05/2001 09:21 ROCHE P2 ABT. TR-P5  
17/05/2001 16:56 650 752 0302  
18/17/01 08:58 FAX 680 752 0302 DELTAGEN  
27/05/2001 16:33 SCIL HOLDING → 06015507520202

S.1

005/006

NR.267 D25

UL

Reiff

X U. Lauer - Reiff

X 28.05.2001

Full Name/Third Inventor

Signature

Date

Residence: ~~85796 München~~ 82377 Penzberg UL  
Germany D. EX

Post Office Address: ~~85796 München~~ Weidenweg 6 UL  
80796 München/Germany 82377 Penzberg

Citizenship: German

(4)  
Full Name/Fourth Inventor Signature Date

Residence: \_\_\_\_\_

Post Office Address: \_\_\_\_\_

Citizenship: \_\_\_\_\_

(5)  
Full Name/Fifth Inventor Signature Date

Residence: \_\_\_\_\_

Post Office Address: \_\_\_\_\_

Citizenship: \_\_\_\_\_

05606635-060401